Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Long-Term Investments (2016 - 2024)

Seres Therapeutics' Long-Term Investments history spans 9 years, with the latest figure at $1.4 million for Q1 2024.

  • For Q1 2024, Long-Term Investments changed 0.0% year-over-year to $1.4 million; the TTM value through Mar 2024 reached $1.4 million, changed 0.0%, while the annual FY2023 figure was $1.4 million, 0.0% changed from the prior year.
  • Long-Term Investments for Q1 2024 was $1.4 million at Seres Therapeutics, roughly flat from $1.4 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $14.9 million in Q2 2021 and bottomed at $1.4 million in Q1 2020.
  • The 5-year median for Long-Term Investments is $1.4 million (2021), against an average of $2.2 million.
  • The largest annual shift saw Long-Term Investments soared 962.79% in 2021 before it crashed 90.58% in 2022.
  • A 5-year view of Long-Term Investments shows it stood at $1.4 million in 2020, then rose by 0.07% to $1.4 million in 2021, then changed by 0.0% to $1.4 million in 2022, then changed by 0.0% to $1.4 million in 2023, then changed by 0.0% to $1.4 million in 2024.
  • Per Business Quant, the three most recent readings for MCRB's Long-Term Investments are $1.4 million (Q1 2024), $1.4 million (Q4 2023), and $1.4 million (Q3 2023).